Story
Mirum Pharma Gains as Investors Await FDA Ruling on Rare Disease Drug
Summary
Shares of Mirum Pharmaceuticals rose in Monday trading as the company approaches a key regulatory decision from the U.S. Food and Drug Administration for its drug candidate, zilurgisertib, which treats an ultra-rare bone disease.
Mirum Pharmaceuticals (NASDAQ: MIRM) shares gained in Monday trading as investors positioned themselves ahead of a pivotal regulatory decision from the U.S. Food and Drug Administration (FDA) for its drug candidate, zilurgisertib. The stock rose 1.0% to $90.23 in afternoon trading on September 25, according to Investing.com.
Key FDA Decision Looms
The FDA is scheduled to announce its verdict on the New Drug Application (NDA) for zilurgisertib on Tuesday, September 26, 2026, which is the drug's Prescription Drug User Fee Act (PDUFA) target date. The agency accepted the application under its Priority Review program, a designation for drugs that, if approved, would represent a significant improvement in treating a serious condition.
Zilurgisertib is an investigational oral ALK2 inhibitor developed to treat fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare and debilitating genetic disorder where bone improperly forms in muscles, tendons, and other soft tissues. Mirum's submission was based on data from its pivotal Phase 2 PROGRESS study.
Company Outlook and Market Context
AdBeyond the upcoming catalyst, other positive factors are supporting investor sentiment. Mirum recently strengthened its financial outlook and leadership team, providing a stable foundation for its clinical pipeline.
Key supporting developments include:
- An increased full-year 2026 net product sales guidance to a range of $680 million to $700 million.
- The appointment of Rob Myers, M.D., a hepatologist with two decades of experience, as Chief Medical Officer.
- Continued support from Wall Street analysts, with multiple firms maintaining Buy or Outperform ratings on the stock.
Shares were also lifted by a broader market rally on Monday. Despite the day's gains, Mirum's stock remains well below its 52-week high of $130, indicating that the outcome of the FDA's decision remains a significant potential catalyst for the company.
Read next
More on Stocks
Bovespa Index Slips 0.27% as Basic Materials, Consumer Stocks Weigh
Brazil's benchmark Bovespa stock index ended Friday's session lower, weighed down by losses in the basic materials and consumption sectors. The decline occurred despite more individual stocks advancing than declining on the exchange.
Bipartisan Bill Seeks to Ban Chinese Optical Transceivers from US Government AI Systems
A group of U.S. lawmakers has introduced legislation to prohibit the federal government from using Chinese-made optical transceivers in sensitive systems, citing national security risks to AI and cloud infrastructure.
Circle CFO Jeremy Fox-Geen to Step Down; Co-Founder Exits Board
Circle Internet Group, the issuer of the USDC stablecoin, announced that Chief Financial Officer Jeremy Fox-Geen will step down. The leadership change also includes the departure of co-founder Sean Neville from the company's board.
Oura IPO Sees Demand Outstrip Supply by Four Times, Report Says
The health and fitness technology company's initial public offering is attracting significant investor interest, with orders reportedly reaching four times the shares available as it seeks to raise up to $2.2 billion.